Cannabis Operator Curaleaf Plunges 46% YTD: Time to Sell or Hold?

Curaleaf Holdings (CURLF) reported a 9% year-over-year revenue decline to $310 million in Q1 2025, primarily due to U.S. market saturation and pricing pressure. Despite a 74% increase in international sales and $26 million in free cash flow, the cannabis operator remains unprofitable amid intensifying competition and regulatory uncertainty, including a proposed federal bill that could restrict hemp-derived products. This challenging environment has led to CURLF shares plunging 46% year-to-date against the industry's 7% rise, resulting in a Zacks 'Sell' rating and signaling elevated near-term risk for investors.

Analysis

Curaleaf Holdings (CURLF) is facing significant fundamental challenges, primarily driven by weakness in its core U.S. market. The company's first-quarter 2025 results revealed a 9% year-over-year revenue decline to $310 million, a direct consequence of market saturation and persistent pricing pressure in the United States. While its international segment demonstrated robust growth of 74% YoY, it constitutes too small a portion of total revenue to offset the domestic downturn. Operationally, the picture is mixed; Curaleaf improved its adjusted gross margin by 250 basis points to 50% and generated $26 million in free cash flow, indicating some success in cost control. However, these efficiencies were insufficient to achieve profitability, and the adjusted EBITDA margin contracted by 180 basis points to 21%. The competitive landscape is intensifying, with peers like Aurora Cannabis and Tilray Brands pursuing similar international and cost-cutting strategies. Compounding these issues is a material regulatory threat from a proposed federal bill that could severely restrict hemp-derived products, a key area for Curaleaf's strategic diversification. The market has reacted negatively to these developments, with the stock plummeting 46% year-to-date, drastically underperforming the industry's 7% gain, and loss estimates for 2026-2027 have widened.

Key Decisions for Investors

• Given the persistent revenue decline in the core U.S. market and intensifying competition, investors should consider the elevated near-term risk and the stock's significant underperformance relative to the sector.
• Monitor future earnings reports for signs of stabilization in domestic sales and pricing, as the current international growth rate is not yet sufficient to reverse the company's negative top-line trajectory.
• Closely track the legislative progress of the proposed federal bill targeting hemp-derived products, as its passage represents a significant downside catalyst that could impair a key growth initiative.
• Evaluate Curaleaf's ability to maintain its improved gross margins and positive free cash flow in subsequent quarters, as this is a critical indicator of operational resilience amid top-line pressure.